The effect of insulhn-like growth factor II (IGF-II) on 
There is no direct evidence that either insulin or the insulinlike growth factors (IGFs) contribute to cancer growth in the human breast (reviewed by Yee, 1992; Callahan and Salomon, 1993) . Genetic evidence is also lacking because the IGF genes and the IGF receptor genes are not frequently amplified in mammary carcnomas and the two major familial susceptibility genes map elswhere (Hall et al., 1990; Berns et al., 1992; Milao et al., 1992; Hebert et al., 1994; Wooster et al., 1994) . However there is accumulating evidence that IGF-H can promote the growth of human breast cacer cell lines in culture and in xenografs (e.g. Brunner et al., 1992) , and that part of this action is mediated through the type 1 IGF receptor (Peyrat and Bo te, 1992) . This cirumstantial evidence suggested the present experimental study.
The purpose was to find out if enhanced IGF-H expression in the mouse mammary gland caused tumours. We report that this is the case for tansgenic mice, in which IGF-H expression is controlled by the sheep -lactoglobulin regulatory elements. Although IGF-H is found at low concentration in the normal milk of humans, cows and rats (Francis et al., 1988; Donovan et al., 1991a,b; Breier et al., 1993) , it now joins a growing list of oncogene products and growth factors whose excess leads to tumour formation in the mouse breast (reviwed by Wang et al., 1994; Webster and Muller, 1994) .
Mateals and mthod
Transgene construction The Igf-2 locus and the constructs are illustrated in Figure 1 .
Sheep P-lactoglobulin (BLG) promoter sequences were subcloned using a Sall site, located approximately 4 kb 5' of the tanscript initiation site, and a XhoI site (formerly a Pvull site, converted using an oligonucleotide linker) within the BLG untranslated leader sequences Harris et al., 1988; Whitelaw et al., 1992) . The Sall-XhoI fragment was ligated at a 5' Sall site within a genomic subclone encompassing all three I-2 coding exons , derived from a largr fragment (Rotwein and HalL 1990 (Hill, 1990) . Human recombinant IGF-1 or IGF-II were used to construct standard curves (UBI, Lake Placid, NY, USA). About 10% of the IGF-II immunoreactivity eluted at <6-8 kDa. Each IGF-I and IGF-II plasma sample was measured within two separate assays. For IGF-I, the intraand interassay coefficients of variation were 10% and 12% respectively, while the sensitivity was 0.4 ng ml-'. The crossreactivity of IGF-II in the assay was less than 1%. For IGF-II, the intra-and interassay coefficients of variation were 8% and 13% respectively. and the minimum level of detection was 5 ng ml-'. The cross-reactivity with IGF-I in the assay was less than 1%.
Results
Breeding history and tumour incidence Mice from each of the four lines which expressed excess Igf-2 mRNA from the transgene in the mammary gland developed mammary tumours (Table I ). These and subsequent tumours were found during routine breeding of females which were heterozygous for the transgene integration site. The tumours occurred in both female founder mice (Laura and Lorna), and in female descendants of the male founders (Leroy and Lesley).
No The number of new tumours found in a particular age interval is expressed as a ratio ofthe number of new tumours detected in that interval over the total numbeF of transgenic females at that age. ND means that observations on transgenic mice without tumours did not continue up to that age and therefore a tumour incidence ratio can not be given. No mammary tumours were found in control transgenic lines which contained different constructs.
transgemc controls was similar to the experimentals (3.3 weeks), and the mean age was 10 months at the end of detailed observations of these controls. Tumour incidence was scored as the number of new tumours which were detected in the transgenic females over a particular time interval, divided by the number of agematched transgenic females which did not develop tumours (Table I) . In this table, the total number of mice decreases with age because many were used for other experiments.
Transgene expression and tumour histologv There were high levels of the transgene Igf-2 transcripts in the primary tumours found in non-lactating females ( Figure  2) . These levels were similar to those found in the normal lactating mammary gland of these transgenic lines (day 10-12 of lactation) and they were maintained in the transplanted tumours. as judged by the reference mGAP and endogenous Igf-2 transcripts (not shown).
Igf 1.216 ( 1.2) Similar size fragnents from a tumour in the Laura line were transplanted to normal hosts and the recipients were killed 4 months after transplantation. The mean number of litters carried by the mating females was 2.9 (range 1 -4) with a mean litter interval of 5.5 weeks.
tumongenic effect is clearly integration site independent and must be a consequence of IGF-II expression. A survey of the mammary gland wet weight, lipid content and histology in these four lines has shown that there are no gross changes in the virgin female gland at around 3 months old (Fisher et al., unpublished) . A detailed analysis of tumour incidence awaits further work but it is already clear that mammary carcinoma development is slow when compared with some transgenic lines which overexpress oncogene products in the mammary gland (see Table I reviewed in Webster and Muller, 1994) . However, the tumours appear much faster than those which develop after extra expression of cyclin Dl in this site (Wang et al., 1994) . Some other transgenic mouse lines with excess IGF-II in adults also develop tumours: hepatocellular and other carcinomas form in the second year of life, when extra IGF-II is expressed from a major urinary protein (MUP) promoter in the liver (Rogler et al.. 1994) .
All four lines of transgenic mice used in the present study had more IGF-I1 protein in the plasma than normal mice (Fisher et al., unpublished) , and the circulating growth factor might increase the incidence of mammary tumours. However, high circulating IGF-II levels are unlikely to be the immediate cause of the tumours observed in the present study because much higher levels are found in other transgenes (Rogler et al.. 1994) , and these do not increase the incidence of mammary tumours in the first year of life. It is therefore probable that it is the local high expression of IGF-II in the mammary gland which accelerates tumour formation. Twnow histology The tumours were classified as mammary carcinoma type B (Squartini and Pingitore, 1994) . The 3-dimensional architecture of the mouse mammary gland is regulated by the mesenchyme during development, while the type of cytodifferentiation of the epithelium is determined by its embryonic origin (e.g. Sakaka et al., 1976) . It follows that the disorganised architecture of a tumour could be caused by a change of either partner in this interaction. Although all primary tumours displayed excess growth of both the stromal and epithelial parts of the gland, it was the epithelial elements which predominated after transplantation. For this reason, we believe that the important change was in the epithelial cells.
Transgene expression and host type Although most of the lines first developed tumours after mutliple pregnancies, the tumours could be readily transplanted into a variety of hosts which were not exposed to the hormonal changes of pregnancy. The tumours continued to express high levels of the transgene Ie-2 transcripts after transplantation to non-pregnant hosts (not shown).
Excess IGF-II is not suficient to cause twnours in all organs In the present work, excess IGF-H expression is shown to contribute to tumour formation in the mouse mammary gland: it is the experimental 'cause' of these tumours. In contrast, excess IGF-II does not cause tumours in several other organs. In adult mice, the cell numbers of the skin and the uterus greatly increase when IGF-H is expressed in these organs, but malignant tumours do not develop from these disproportionate overgrowths . Further, the extent of normal fetal tissue growth depends directly or indirectly on the normal action of the endogenous Igf-2 genes (DeChiara et al., 1990; Baker et al., 1993; Lee et al., 1993) . It is therefore unlikely that a single genetic change in IGF-ll expression is sufficient in itself to make cells malignant, and IGF-H presumably has ihis tumorigenic action in the mammary gland because it increases the probability that other genetic changes will occur in this organ.
Action of IGF-II in tmnourformaton
The IGFs have long been known to maintain the health of cells in culture and there is now a plausible mechanism for this action (Conover et al., 1993; . It is certainly possible that IGF-H's main function in tumour formation is to increase cell survival (e.g. Biddle et al., 1988; Harrington et al., 1994) , and render cells competent to respond to other growth factor signals: twin actions which are emphasised by IGF-H expression in mouse pancreatic tumours . In mammary tumorigenesis, an effect of IGF-H on cell survival might first show up as inhibition of the apoptosis which accompanies mammary gland regression during the 4 days after weaning the young (Guenette et al., 1994) . We have not yet measured this feature.
It is also possible that the mammary gland is particularly susceptible to IGF-II driven tumorigenesis because the gland is a major organ of fat metabolism (Williamson, 1991) , and high carcass fat is often associated with frequent tumour development in mice (e.g. Wolff et al., 1986; Wolff 1987) . IGF-l certainly has the capacity to alter lipid metabolism, with a relatively high fat content retained in organs expressing high levels of IGF-H (DaCosta et al., 1994 
